Comparison of Silodosin and Tamsulosin for Medical Expulsive Therapy in Patients With Ureteral Stones

This study was designed as a prospective, randomized, open-label, controlled trial conducted at the Urology Department of Sir Ganga Ram Hospital, Lahore, over a period of 12 months. Ethical approval was obtained from the institutional review board, and written informed consent was secured from all participants.

Participants included adults aged 18 to 60 years with a single, unilateral ureteric stone measuring 5 to 10 mm, confirmed by non-contrast CT scan. Patients with a history of ureteral surgery, congenital anomalies, severe renal impairment (serum creatinine above 1.5 mg/dL), pregnancy, lactation, urinary tract infection, or those using calcium channel blockers or other alpha-blockers were excluded. A total of 180 eligible patients were randomized into two groups: 89 patients received Tamsulosin 0.4 mg daily, while 93 patients received Silodosin 8 mg daily.

Both groups received standard analgesia with diclofenac sodium 50 mg as needed and were advised to maintain adequate hydration. Treatment continued until stone expulsion or for a maximum of 28 days. Patients were monitored weekly through clinical evaluation and imaging (ultrasound or X-ray), and adverse events such as dizziness, ejaculatory dysfunction, and headaches were recorded using standardized questionnaires.

Data analysis was performed using SPSS version 25.0. Continuous variables were compared using Student's t-test, while categorical variables were assessed with Chi-square or Fisher's exact test. A p-value of less than 0.05 was considered statistically significant.

Inclusion criteria

• Patients between ages 18 years - 55 years.
• Solitary unilateral ureteral stone
• Stone sizes less than 10 mm measured on non-contrast computed tomography of kidney, ureter and bladder.
• Stones being treated primarily with medical expulsive therapy
• Radio opaque Stone

Exclusion criteria

• Pregnancy
• Untreated UTI
• Bleeding disorders
• Obstruction distal to stone
• Serum Creatinine > 1.3 mg/dl in males and > 1.2 mg/dl in females.
• Congenital renal anomaly/ skeletal malformation
• Previous treatment for the same stone (PCNL/ URS / push back)
• Solitary Kidney
• Prior JJ stent insertion
• Bilateral ureteral stone